Recent work with the guinea pig has indicated that the mechanism of quinacrine might be an indirect one-that quinacrine might serve to stimulate adrenal cortical activity and that increased production of adrenocortical hormones might be directly responsible for clinical improvement. The purpose of this paper is to report the results of experiments designed to test the possibility of this mechanism in human subjects.
Chloroquine (Aralen, SN-7618, 7-chloro-4-(4-diethylamino, -1 -methylbutamino) quinoline) has been chosen for this study because its therapeutic efficiency has been established as equal or superior to that of quinacrine in both parasitic and light-sensitive diseases, while it has fewer toxic or undesirable properties.
THEn APEUTIC USES OF CHLOEOQUINE
A review of the medical applications of chloroquine will serve to introduce the presently known data about its mode of action. The drug was adopted by the United States Army in 1947 (1) and maintains its position ten years later in the United States Dispensatory (2) as tbe most effective and least toxic agent for the suppressive therapy of malaria during exposure to infection.
In addition, it is the drug of choice iu the treatment of hepatic amebiasis (3) . It is also highly effective in the treatment of leishmaniasis (4) . The light-sensitive dermatoses constitute a second category in which the usefulness of chloroquine is well established. Clinical studies have shown that it is the most effective single drug for the treatment of chronic discoid lupus erythematosus (5) . It holds the same position in respect to polymorphous light eruption, and is, in addition, an effective prophylactic agent (6) . A third category comprises a number of diseases in which ehloroquine has been tried, but in which its usefulness is questionable, erratic, or has not yet been * From the Department of Dermatology, University of Pennsylvania, Philadelphia, Pa.
Supported by United States Army Research
Grant DA-49-007-MD-154.
Received for publication December 24, 1957. established. A report of the successful treatment of 10 of a series of 12 cases of larva migrans still awaits confirmation by other clinicians (7). The most extensive long-term study of chloroquine in the therapy of rheumatoid arthritis (8) is moro optimistic than convincing. Used in two cases of auricular fibrillation (9), chloroquine was more toxic and less satisfactory than quinidine. Dermatologic diseases in which ehloroquine has been employed but has not won general acceptance include-aerodermatitis chroniea atrophicans (10), lichen planus and psoriasis (11), vitiligo (12) , rosaeea (13) , and sareoidosis (14) . The UVL absorption spectrum of ch]oroquine corresponds to the range Beal (26) demonstrated to be responsible for 2 eases of solar urticaria. Cahn, et al. (27) , however, were not only unable to demonstrate any change in the minimal erythema dose of UVL in subjects taking chloroquine at or above therapeutic levels, but were also able to prove that the wave lengths causing polymorphous light eruption did not correspond to those against which ehloroquine might be expected to protect their patients. They concluded that the sun-screening action of the drug was not responsible for its therapeutic effect in this disease.
An "anti-inflammatory" action has been reported for chloroquine by Blaich and Gerlach (28) . Nagy (29) and his group, working with quinacrine, showed that guinea pigs and cats pretreated with this drug could withstand doses of histamine lethal to untreated controls. Searching for the cause of this "anti-histaminic" effect, they found that the lung histaminase activity of quinacrine-treated guinea pigs was the same as that of controls. They did find, however, that the adrenal glands of the quinacrine-treated guinea pigs were markedly enlarged. Histological examination showed that the cortex was hypertrophied and in the secretory phase. They reported a 30% increase in 17-ketosteroid production in the treated group. From this evidence in the guinea pig, Nagy, et al. proposed that stimulation of the adrenal cortex to increased hormone production might play a role in the mechanism of the therapeutic action of quinacrine. However, since this effect did not occur in all subjects nor correlate with their test for "antiinflammatory" action they concluded that the 4. Thies (33) has reported that locally-injected chloroquine is an effective therapy in chronic discoid lupus erythematosus and OttolenghiLodigiani (34) has reported similar results for quinacrine.
With this background of promising but contradictory evidence, we undertook the present study of the effect of long-term, high dosage chlosoquine administration on the function of the normal human adrenal cortex.
METHOD OF RESEARCH
Subjects. Two groups of 8 healthy male inmates of a penal institution, age 20 to 50, were randomly selected. The test group contained 3 Negroes, the control group 2.
Dosage. The test group received three 250 mg. enteric-coated tablets of cliloroquine-phosphate (total-750 mg.) daily at 11:00A.M. for 28 days. The control group received three 325 mg. tablets of calcium lactate (placebo) daily at the same hour for the same period.
Eosinophile counts. Five cc. of venous blood were collected using the anticoagulant, dilution, and counting methods described by Thorn ci al. (35) . The number of eosinophiles reported per mm3 represents the average of four counts. The initial sample was taken just prior to the first dosage of chloroquine or placebo, the second sample 4 hours later. Subsequent samples, taken 1,2,3,4,5,6,8, 12, 15, 20, 22, 26, 28, and 42 days after the start of testing, were drawn at the same hour as the second sample (3:00 P.M.), with the exception of the twentieth day sample which was taken at 11:00 A.M. Spot-check recounts showed minimal variation from the reported figures.
White cell counts. Using standard laboratory technic, total white cell counts were performed using the blood drawn for the 15 6.8
RESULTS
Complaints of headache and gastro-intestinal disturbance were no more common in the test group than among the controls, but complaints of visual disturbance, while more common in the test group, were also made by the controls. Subjects were otherwise apparently healthy throughout the test period.
Eosinophile counts for the test group are presented in Table 1 and Figure 1 , and for the control group in Table 2 and Figure 2 . Any significance attributed to variations in the eosinophile level among the test group must be evaluated in the light of variations seen in the control group.
Among the latter, fluctuations of the order of 50% are seen at different times in several of the subjects, and wide variation is usual, rather than exceptional. The same pattern generally applies to the test group. When both groups are plotted graphically they are seen to maintain a rather uniform group pattern. Seen thus we feel that no significant depression of the eosinophile count can be claimed to follow ehloroquine administration in normal human subjects under the above test conditions. Table 3 compares the eosinophile counts taken on the 15th and 26th days of the test period with total white cell counts taken from the same blood samples. The two values are seen to be independently variable. Table 4 and Figures 3 and 4 present the results of 17-hydroxycorticosteroid and 17-ketosteroid determinations made on a 24-hour urine specimen collected on the 27th test day. Thorn et at. (38) state that a change in total 17-hydroxycorticoid excretion is a more reliable indicator of adrenal cortical activity than an alteration in 17-kctosteroids. It will be seen that all the test subjects' 17-hydroxycorticostcroids fell well within normal limits. Low values for 17-kctosteroids in 5 of 8 test subj ects may be related to Nelson and Fitzhugh's (32) finding that the rat testicle showed marked atrophy in response to prolonged chloroquine administration. Our own findings of low or normal steroid levels show that chloroquinc does not increase adrenocortical activity. COMMENT A review of the literature has shown that chloroquine's therapeutic mechanism may be rclatcd to its nuclco-protcin binding property, to its interference with a number of biochemical systems, or to its light-screening properties.
Some objections to each of these theories have been previously discussed. The proposal of Nagy's group that chloroquinc may act indirectly by stimulating the adrenal cortex to increased activity has not been substantiated by our findings in human subjects. At present the mode of action of chloroquinc, particularly in the lightsensitive dermatoscs remains obscure. The influence of this drug on known biochemical processes, perhaps on the redox potential which Langhof and Muting (39) believe to play a key role in light-sensitive diseases, would seem to offer an interesting field for research.
SUMMARY
(1) A report is given of an investigation of the effect of long term, high-dosage chloroquine on human adrcno-cortical activity.
(2) Eosinophilc counts and corticosteroid assays indicated no increase in adrenal activity during one month of chloroquinc therapy. CHLOROQUIN GROUP
